ArticleCancer immunology research2017
Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer immunology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 40 citations in OpenAlex.
- Sonoselective Transfection of Glioma Endothelium.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances in miRNA-Mediated Bidirectional Crosstalk and Immune Evasion Mechanisms Between Lung Cancer Cells and CD8International journal of molecular sciences · 2026Review
- An epigenetic switch in vascular phenotype augments anti-tumor immunity.Angiogenesis · 2026Article
- Chronic XBP1s-mediated activation of the unfolded protein response impairs CD8Frontiers in immunology · 2026Article
- The Role of Distinct Cancer-Associated Fibroblast Subtypes in Prostate Cancer Immunotherapy.International journal of biological sciences · 2026Review
- Characterization of cancer-associated fibroblast populations that promote tertiary lymphoid structure formation in murine melanoma tumors.Frontiers in immunology · 2026Article
- Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy.Molecular cancer · 2025Review
- Organoid: a promising solution to current challenges in cancer immunotherapy.npj biomedical innovations · 2025Review
- The fibroinflammatory response in cancer.Nature reviews. Cancer · 2025Review
- Reciprocal Modulation of Tumour and Immune Cell Motility: Uncovering Dynamic Interplays and Therapeutic Approaches.Cancers · 2025Review
- The research progress on meningeal metastasis in solid tumors.Discover oncology · 2025Review
- Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.Journal of hematology & oncology · 2025Review
- SubvertingBiology · 2024Review
- Endothelial cell Notch signaling programs cancer-associated fibroblasts to promote tumor immune evasion.Research square · 2024Article
- Localization, tissue biology and T cell state - implications for cancer immunotherapy.Nature reviews. Immunology · 2023Review
- Priming a vascular-selective cytokine response permits CD8Nature communications · 2023Article
- Barriers to immune cell infiltration in tumors.Journal for immunotherapy of cancer · 2023Review
- Adhesion analysis via a tumor vasculature-like microfluidic device identifies CD8Cell reports · 2023Article
- Article
- Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine.Journal for immunotherapy of cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Amber N WoodsCarter Immunology Center and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia.
Ashley L WilsonCarter Immunology Center and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia.
Nithya SrivinisanCarter Immunology Center and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia.
Jianhao ZengCarter Immunology Center and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia.
Arun B DuttaCarter Immunology Center and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia.
J David PeskeCarter Immunology Center and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia.
Eric F TewaltCarter Immunology Center and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia.
Randal K GreggCarter Immunology Center and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia.
Andrew R FergusonCarter Immunology Center and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia.
Victor H EngelhardCarter Immunology Center and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia. vhe@virginia.edu.
Carter Center · US
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1MCancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4MINTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2MQuality and location of presented Ag as determinants of tumor-specific immunityR01CA078400 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI ENGELHARD, VICTOR H · 1998 to 2012
$4.4MAutoimmune vitiligo and tolerance in the immune response to a melanoma antigenR01AI068836 · NIAID · UNIVERSITY OF VIRGINIA · PI ENGELHARD, VICTOR H · 2007 to 2011
$2.1MFluorescence molecular tomography to study T cell infiltration into tumorsR21CA185955 · NCI · UNIVERSITY OF VIRGINIA · PI ENGELHARD, VICTOR H, KELLY, KIMBERLY A. · 2014 to 2015
$372kThe Role of Lymphoid Environments in Guiding T Cell MigrationF32AI072818 · NIAID · UNIVERSITY OF VIRGINIA · PI FERGUSON, ANDREW R. · 2007 to 2009
$130kImpact of Intrinsic Factors on Vitiligo and MelanomaF32CA121916 · NCI · UNIVERSITY OF VIRGINIA · PI GREGG, RANDAL · 2006 to 2006
$44kNCI NIH HHS F32 CA121916NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA078400NCI NIH HHS R21 CA185955NCI NIH HHS T32 CA009109NIAID NIH HHS F32 AI072818NIAID NIH HHS R01 AI068836NIAID NIH HHS T32 AI007496NIGMS NIH HHS T32 GM007267
Abstract
Although CD8
Indexed as
Gene Expression Regulation, NeoplasticAdaptive ImmunityAnimalsBiomarkersCD8-Positive T-LymphocytesCell Line, TumorChemokine CXCL9E-SelectinIntegrin alpha4beta1LigandsMelanoma, ExperimentalMiceModels, BiologicalNeoplasmsNeovascularization, PathologicReceptors, Lymphocyte HomingBiomarkersChemokine CXCL9CXCL9 protein, humanE-SelectinIntegrin alpha4beta1LigandsReceptors, Lymphocyte HomingVascular Cell Adhesion Molecule-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.